Pharmaceuticals

Aspire Biopharma

Aspire Biopharma Reports Q3 Earnings with Net Loss of $19.77 Million

Aspire Biopharma Holdings Inc. Reports Q3 2025 Net Income and Signs Non-Compete Agreements

Aspire Biopharma Discusses Strategic Plans for Sublingual High-Dose Aspirin at CPHI Trade Show

Aspire Biopharma Submits Patent Application for New Sublingual Drug Delivery Platform

Aspire Biopharma to Present Latest Advancements in Sublingual Drug Delivery at Noble Capital Markets

Aspire Biopharma to Submit New Drug Application for Sublingual Aspirin in Late 2025

Aspire Biopharma released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.0401

Aspire Biopharma released FY2025 Semi-Annual Earnings on August 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.4101

Aspire Biopharma to debut new supplement BUZZ BOMB at FITCON and Fit Expo

Aspire Biopharma Completes Phase 1 Trial of Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma moves headquarters to Florida

Aspire Biopharma showcases sublingual drug delivery technology

Aspire Biopharma Holdings Inc. Names Michael Howe as New CEO

Aspire Biopharma Director Buys Company Shares

Aspire Biopharma to launch BUZZ BOMB™ in Q3 2025

Aspire Biopharma Initiates Clinical Trial for High-Dose Aspirin Formulation

Aspire Biopharma released FY2025 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -0.4207

Aspire Biopharma released FY2024 Q4 earnings on May 13 (EST), actual revenue USD 0, actual EPS USD -0.0016

Aspire Biopharma released FY2024 Annual Earnings on May 13 (EST), with actual revenue of USD 0 and EPS of USD -0.0029

Aspire Biopharma Holdings reaches debt settlement with lender and extends loan maturity

Cidara Therap

CYPHERPUNK TECHNOLOGIES INC

Invivyd

Traws Pharma

UTime

Binah Capital

SmartKem

YD Bio

Oncology Institute

BioAtla

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap